戻る Agenda
Spotlight Symposia: Three Paths to Success in a Post-COVID World
Session Chair(s)
WCG
United States
- The status of market uptake for select CNS clinical trials by the pharma industry: rejuvenated interest and continued challenges ahead. - Continuously improved solutions are no longer a nice-to-have. - COVID implications on patient selection, study analytics, and placebo response reduction. - The future of CNS drug development.
Speaker(s)
Bob Dagher
WCG MedAvante-ProPhase, United States
Chief Medical Officer
Mark Gregory Opler, PhD, MPH
WCG MedAvante-ProPhase, United States
Chief Research Officer